Skip to content
Biodatica
Start free

Chong Kun Dang Pharmaceutical

Seoul, Seoul

OncologyFiled/Approved
Compare Sign in to watch

What changed

NIH R01 · $0.4M · Mechanistic insights into a novel cell cycle regulator complex for cancer therapy

2mo agoNew grantMay 11, 2026Source filing (opens the source filing in a new tab)

Momentum

62no change

Momentum 62 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

77 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $415k · non-dilutive

    May 7, 2026

    UT SOUTHWESTERN MEDICAL CENTER · PI CHOI, JIN HUK · NIAID · award ends Apr 30, 2031 · Mechanistic insights into a novel cell cycle regulator complex for cancer therapy

    NIH RePORTER · NIH RePORTER 11341206 (opens the source filing in a new tab)

  2. Trial

    PHASE4 registered

    Aug 14, 2025

    Heart Transplant · NOT_YET_RECRUITING · sponsor: Chong Kun Dang Pharmaceutical · Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

    ClinicalTrials.gov · NCT06942156 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Mar 11, 2025

    Hepatocellular Carcinoma (HCC), Radioembolization · RECRUITING · sponsor: Seoul National University Hospital · Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

    ClinicalTrials.gov · NCT06773845 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources